Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

Executive Summary

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

Advertisement

Related Content

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
Allergan Thinks It’s Ready To Withstand Restasis Generics
Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication
J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo
Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
Allergan Fights Generic Headwinds, Activist Investors
Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel